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The gut hormone, ghrelin, is the only known peripherally derived orexigenic signal. It
activates its centrally expressed receptor, the growth hormone secretagogue receptor
(GHS-R1a), to stimulate food intake. The ghrelin signaling system has recently been
suggested to play a key role at the interface of homeostatic control of appetite and
the hedonic aspects of food intake, as a critical role for ghrelin in dopaminergic
mesolimbic circuits involved in reward signaling has emerged. Moreover, enhanced
plasma ghrelin levels are associated with conditions of physiological stress, which may
underline the drive to eat calorie-dense “comfort-foods” and signifies a role for ghrelin
in stress-induced food reward behaviors. These complex and diverse functionalities of
the ghrelinergic system are not yet fully elucidated and likely involve crosstalk with
additional signaling systems. Interestingly, accumulating data over the last few years
has shown the GHS-R1a receptor to dimerize with several additional G-protein coupled
receptors (GPCRs) involved in appetite signaling and reward, including the GHS-R1b
receptor, the melanocortin 3 receptor (MC3), dopamine receptors (D1 and D2), and more
recently, the serotonin 2C receptor (5-HT2C). GHS-R1a dimerization was shown to affect
downstream signaling and receptor trafficking suggesting a potential novel mechanism for
fine-tuning GHS-R1a receptor mediated activity. This review summarizes ghrelin’s role in
food reward and stress and outlines the GHS-R1a dimer pairs identified to date. In addition,
the downstream signaling and potential functional consequences of dimerization of the
GHS-R1a receptor in appetite and stress-induced food reward behavior are discussed.
The existence of multiple GHS-R1a heterodimers has important consequences for future
pharmacotherapies as it significantly increases the pharmacological diversity of the
GHS-R1a receptor and has the potential to enhance specificity of novel ghrelin-targeted
drugs.
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INTRODUCTION
Appetite regulation, food intake and diet are closely inter-
twined with mood regulation and stress perception and stress
response (Oliver and Wardle, 1999; Gibson, 2006; Morrison,
Abbreviations: ACTH, adrenocorticotropic hormone; AgRP, agouti-related pep-
tide; ARC, arcuate nucleus; BRET, bioluminescence resonance energy trans-
fer; CART, cocaine- and amphetamine-regulated transcript; CCK, cholecys-
tokinin; CPP, conditioned place preference; CSDS, chronic social defeat stress;
CRF, corticotrophin-releasing factor; DA, dopamine; GH, growth hormone;
GHRH, growth hormone-releasing hormone; D1, dopamine 1 receptor; D2,
dopamine 2 receptor; FRAP, fluorescence recovery after photobleaching; GHS-
R1a, growth-hormone secretagogue receptor; GOAT, ghrelin O-acyl transferase;
GPCR, G-protein coupled receptors; Hek, human embryonic kidney cells;
HPA, hypothalamic-pituitary-adrenal; MC3, melanocortin 3 receptor; NAcc,
nucleus accumbens; NPY, neuropeptide Y; NTS, nucleus of the solitary tract
(nucleus tractus solitarii); PVN, paraventricular nucleus; POMC, proopiome-
lanocortin; SN, substantia nigra; TIRF, total internal reflection fluorescence imag-
ing; UPC2/3, uncoupling proteins 2 and 3; VTA, ventral tegmentum; 5-HT,
serotonin (5-hydroxytryptamine); 5-HT2C, serotonin 2C receptor; 6-OHDA, 6-
hydroxydopamine.
2009; Dallman, 2010). Obesity and the metabolic syndrome,
which can be defined as a combination of comorbid medical
disorders, including atherosclerosis, hypertension, insulin resis-
tance or diabetes mellitus type II, glucose intolerance, dyslipi-
demia, and a general pro-inflammatory phenotype (Cheng and
Leiter, 2006; Mikhail, 2009), have been identified as environ-
mental risk factors for affective psychiatric disorders, includ-
ing anxiety and depression (McElroy et al., 2004; Goldbacher
and Matthews, 2007; Kloiber et al., 2007; Gariepy et al., 2010;
Marijnissen et al., 2011). Epidemiologic data even suggests that
obesity is associated with a 25% increased incidence of anxi-
ety and mood disorders (Simon et al., 2006). In addition, major
depression in adolescence is linked with a higher risk for obe-
sity in adulthood (Richardson et al., 2003). Moreover, metabolic
conditions may be exacerbated in depression and vice versa,
which indicates a reciprocal link (McElroy et al., 2004; Simon
et al., 2006; de Wit et al., 2010; Luppino et al., 2010; Marijnissen
et al., 2011). Likewise, stress significantly impacts on food intake
www.frontiersin.org August 2013 | Volume 7 | Article 148 | 1
Schellekens et al. Dimerization of the GHS-R1a receptor
in humans and animals and may promote metabolic distur-
bances (Block et al., 2009; Dallman, 2010; Maniam and Morris,
2012). Interestingly, stress-induced hyperphagia and subsequent
increases in body weight and obesity are also associated with
major depressive disorders in humans (Novick et al., 2005; Simon
et al., 2006; Kloiber et al., 2007). Moreover, acute stress responses
are reduced following intake of palatable rewarding foods,
potentially explaining the phenomenon of “comfort eating”
observed in stressed individuals as self-medication for stress relief
(Dallman et al., 2003).
Ghrelin, a 28 amino acid stomach-derived peptide (Kojima
et al., 1999), is currently the only described orexigenic hormone
from the periphery, acting centrally to increase food intake and
modulates the body’s metabolism via centrally activated mecha-
nisms (Tschop et al., 2000; Nakazato et al., 2001; Kojima et al.,
2004; Andrews, 2011). Peripheral ghrelin mediates its appetite-
inducing effects centrally, after passing through the blood brain
barrier (Banks et al., 2002, 2008). Recent experiments by Schaeffer
and colleagues have confirmed that the hypothalamus directly
senses circulating ghrelin from the periphery to modify energy
status (Schaeffer et al., 2013). This study demonstrated that circu-
lating ghrelin rapidly binds neurons in the vicinity of fenestrated
capillaries using in vivo multiphoton microscopy together with
fluorescently labeled ligands. Interestingly, it was also shown that
the number of labeled cell bodies varies with feeding status,
suggesting a potential differential ability to sense ghrelin under
altered metabolic conditions. In addition, in both rodents and
humans, ghrelin also reaches the brain via vagal afferents to the
nucleus of the solitary tract (NTS) in the brain stem with further
projections to the arcuate nucleus (ARC) of the hypothalamus
(Asakawa et al., 2001b; Date et al., 2002; Williams et al., 2003;
le Roux et al., 2005). However, contradictory results exists in
rats, disputing the role of vagal afferents in the acute eating-
stimulatory effect of peripheral ghrelin (Arnold et al., 2006).
When the orexigenic hormone ghrelin activates its recep-
tor, the growth-hormone secretagogue receptor (GHS-R1a), it
stimulates appetite and food intake but also mediates a multi-
tude of additional biological activities, including the secretion
of growth hormone (GH), glucose and lipid metabolism and
gastrointestinal motility, which together maintain the body’s
energy homeostasis (for review see Schellekens et al., 2010).
Moreover, ghrelin contributes to the accumulation of adipose
tissue via the promotion of carbohydrates over fat as energy
substrate (Tschop et al., 2000). The ghrelinergic system has
therefore received considerable attention in the pharmaceutical
industry as a promising target in obesity treatment and other
eating disorders (Horvath et al., 2003; Zorrilla et al., 2006; Leite-
Moreira and Soares, 2007; Moulin et al., 2007; Soares et al.,
2008; Chollet et al., 2009; Lu et al., 2009; Schellekens et al., 2010;
Patterson et al., 2011; Yi et al., 2011). In addition, accumulating
data has revealed that the ghrelinergic system has an impor-
tant function in other behaviors related to food intake and plays
a pivotal role in the mesolimbic dopaminergic circuitry, which
is responsible for various non-homeostatic, hedonic rewarding
and motivational aspects of food intake (for review see Dickson
et al., 2011; Egecioglu et al., 2011; Skibicka and Dickson, 2011;
Perello and Zigman, 2012; Schellekens et al., 2012b; Skibicka
et al., 2012). More recently, ghrelin has been shown to be
involved in mediating a stress response and to mediate stress-
induced food reward behavior (Lutter et al., 2008; Chuang
and Zigman, 2010; Patterson et al., 2010, 2013; Chuang et al.,
2011; Diz-Chaves, 2011; Schellekens et al., 2012b; Spencer et al.,
2012).
Thus, current research indicates a potential link between ghre-
lin and affective disorders, such as anxiety and depression. In
line with this hypothesis are the decreased plasma ghrelin lev-
els often observed in depressed patients (Barim et al., 2009) (but
also see Schanze et al., 2008; Kluge et al., 2009). Furthermore,
recent data also demonstrates that ghrelin administration in
patients with major depression has some antidepressant effects
(Kluge et al., 2011), which is in support of the involvement
of ghrelin in the etiology of depressive disorders. Interestingly,
a ghrelin gene polymorphism has also been linked with the
symptomatology of depression (Nakashima et al., 2008). It is
clear, that the ghrelin signaling system is involved in a mul-
titude of centrally regulated functionalities, which exceeds far
beyond appetite regulation, energy homeostasis and GH secre-
tion. This is reinforced by the ubiquitous expression of the
GHS-R1a receptor in both the periphery as well as the brain
(Howard et al., 1996; Guan et al., 1997; Zigman et al., 2006).
In particular, the extra-hypothalamic expression of the GHS-
R1a receptor, including in the ventral tegmental area (VTA)
and nucleus accumbens (NAcc), hippocampus and amygdala,
reinforces a function for ghrelin signaling in the hedonic regu-
lation of food intake (Guan et al., 1997; Zigman et al., 2006).
Together, this data suggests that the role of the ghrelinergic sys-
tem in obesity, appetite and food intake now extends toward
the reward and motivation pathways as well as to the signal-
ing pathways involved in stress, psychiatric disposition (i.e.,
mood) and affective disorders such as anxiety and depression.
However, it is currently unclear what the exact molecular mech-
anisms are that mediate this biological diversity of the GHS-
R1a receptor. We hypothesize that the differential GHS-R1a
receptor signaling events can be explained through crosstalk
with additional neuropeptide systems and dimerization with
other G-protein coupled receptors (GPCRs) (Schellekens et al.,
2013a,b).
This review outlines ghrelin’s role in food reward signaling
and stress, highlights the identified GHS-R1a dimer pairs to date,
and discusses the potential functional consequences of dimer-
ization of the GHS-R1a receptor, with particular focus on its
key role in appetite and stress-induced food reward behavior.
The ability of the GHS-R1a receptor to form heterodimers with
multiple GPCRs involved in the homeostatic or hedonic regu-
lation of food intake and potentially also in the stress response
significantly increases its pharmacological diversity (Figure 1).
Further understanding of the biological significance of GHS-
R1a receptor dimers in the neuroendocrine system may pertain
to potential new molecular targets and novel strategies for the
treatment of stress-associated psychiatric disorders of anxiety as
well as eating disorders and metabolic disturbances leading to
obesity.
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FIGURE 1 | Heterodimerization of G-protein coupled receptors.
G-protein coupled receptor (GPCR) oligomerization has several biological
functions and consequences. Receptor dimerization can play a role in
receptor maturation and correct trafficking (1). Specific ligand binding
can dynamically regulate heterodimerization (2) and allostery can
enhance or suppress downstream signaling (3). In addition, GPCR
heterodimerization may demonstrate preferential G protein coupling (4).
Finally, agonist-promoted GPCR endocytosis and co-internalization may
lead to signal attenuation (5). +/− indicates increase or decrease,
respectively.
GHRELIN SIGNALING IN STRESS AND REWARD
The hedonic signaling following ingestion of palatable and
calorie-rich food is increasingly being recognized as an important
underlying cause for the increase in obesity worldwide, as the
overconsumption of calorie-dense foods extends far beyond
the individual’s nutritional needs (Berthoud, 2006). Obesity-
associated habitual overconsumption is mediated by rewarding
feelings associated with eating as well as by a natural sensi-
tivity to food stimuli. Stress also affects feeding behavior in
humans (Oliver andWardle, 1999; Gibson, 2006; Dallman, 2010).
Interestingly, while some individuals display a stress-induced
hyperphagia, others display hypophagia, but an overall increased
consumption of highly palatable and caloric-dense foods com-
pared to non-stressed controls is reported (Gibson, 2006;
Dallman, 2010). Stress-related psychiatric disorders, including
depression, are also linked with extremes in eating behav-
ior according to criteria within the diagnostic and statistical
manual of mental disorders (DSM-IV) (American Psychiatric
Association, 1994). In addition, the experience of intense stress
during childhood represents a strong risk factor to develop
depression later in life (O’Mahony et al., 2009; Heim and Binder,
2012). Moreover, these same early life stress events have been
associated with metabolic abnormalities later in life (Kaufman
et al., 2007). The complex bi-directional relationship between
stress, mood and feeding behavior are regulated by converg-
ing neuronal pathways mediating appetite and subsequent food
intake and circuitries that modulate stress via the hypothalamic-
pituitary-adrenal (HPA) axis (Kyrou and Tsigos, 2007; Ulrich-Lai
and Herman, 2009; Dallman, 2010; Finger et al., 2011, 2012b;
Maniam and Morris, 2012; Schellekens et al., 2012b; Scott et al.,
2012). The current knowledge on the role of the metabolic pep-
tide ghrelin in this non-homeostatic food intake behavior is
discussed below.
FEEDING BEHAVIOR AND STRESS RESPONSE
Stress response in mammals is mediated via the sympathetic
nervous system and involves activation of the HPA axis, immuno-
logical changes as well as changes in neural and endocrine
mechanisms (McEwen, 2007; Ulrich-Lai and Herman, 2009).
The behavioral and physiological responses following stress are
initiated with the release of corticotrophin-releasing factor (CRF)
from specialized neurons in the paraventricular nucleus (PVN)
of the hypothalamus, which subsequently induces the release of
adrenocorticotropic hormone (ACTH) from the anterior pitu-
itary gland into the general circulation. This ultimately stimulates
the release of the glucocorticoid corticosterone (or cortisol in pri-
mates) from the adrenal cortex. A negative feedback loop exists,
which is activated after the elevation in circulating glucocorticoids
and prevents further stimulation of the HPA axis via activation
of glucocorticoid receptors expressed on the hypothalamus, hip-
pocampus, medial prefrontal cortex, and pituitary gland (Jones
et al., 1977; Mahmoud et al., 1984; Sapolsky et al., 1984, 2000;
Diorio et al., 1993; Radley et al., 2008; Ulrich-Lai and Herman,
2009). The acute activation of the HPA axis following stress pro-
motes survival via physiological and behavioral adaptations and
aims to re-establish the challenged body equilibrium. However,
exposure to chronic stress and overstimulation of the HPA-axis
can result in physiological alterations with detrimental effects and
metabolic disturbances, including obesity (Black, 2006; McEwen,
2007). Vice versa, obesity constitutes a chronic stressful state
that may cause HPA axis dysfunction (Kyrou and Tsigos, 2007).
Interestingly, and in line with the above, the HPA axis has been
linked with the control of metabolism and neurotransmitter
release in several brain regions, facilitating the appropriate chan-
neling of energy resources to promote survival following stress
(Kyrou and Tsigos, 2007; McEwen, 2007; Dallman, 2010; Bowers
et al., 2012).
It is likely that the neurobiological mechanisms at the heart
of the relationship between food intake and stress responses and
the neuronal circuitry of fear, underlying anxiety, are evolutionary
selected to function as defensive survival mechanism regulating
our response to environmental threats (Siervo et al., 2009). The
link between stress and feeding behavior is reinforced by the
overlapping neuronal circuitry between the two and involves the
same neuropeptides (Bowers et al., 2012; Maniam and Morris,
2012). The stress response following HPA axis activation, and the
central mechanisms that regulate appetite and subsequent food
intake, proopiomelanocortin (POMC) or neuropeptide Y and
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agouti-related peptide (NPY/AgRP), both converge on the PVN
and on the CRF-producing neurons within this region. In addi-
tion, several peripherally derived hormones and neuropeptides
regulating appetite and satiety also play a key role in anxiety-
like behavior, highlighting the importance of a bi-directional
relationship in anxiety-related mechanisms and eating disorders.
For example, the orexigenic neuropeptide NPY (Stanley and
Leibowitz, 1985; Heilig et al., 1989) has been shown to exert
anxiolytic effects and the anorexigenic peptide cholecystokinin
(CCK) (Gibbs et al., 1973) induces panic-like effects (Strohle
et al., 2000), impacting on general anxiety and stress-related
behavior. Moreover, cocaine- and amphetamine-regulated tran-
script (CART) is both satiety inducing as well as a mediator of
anxiety-like behaviors (Kristensen et al., 1998; Stanek, 2006) and
neuropeptide S has both anorexigenic (Smith et al., 2006) and
anxiolytic (Xu et al., 2004) responses. Furthermore, neuropep-
tide expression has been shown to be altered following acute and
chronic stressors (Bowers et al., 2012). Likewise, the CRF system
is implicated in the regulation of energy balance and in the patho-
physiology of obesity and eating disorders. The corticostriatal-
hypothalamic circuitry mediates the motivation to obtain food
rewards and to promote the overconsumption of palatable foods
beyond acute homeostatic needs (Kelley et al., 2005). However,
the precise effects of chronic psychosocial stress on neuropeptide
and gut hormone expression under conditions of obesity as well
as under conditions of malnutrition or anorexia nervosa have not
been extensively explored. However, as most neuropeptides con-
vey onto centrally expressed GPCRs, we hypothesize a crucial role
for GPCR dimerization and oligomerization.
GHRELIN SIGNALING IN STRESS
Recently, a key role for ghrelin in anxiety and in stress-induced
food intake behavior has been suggested (Chuang and Zigman,
2010; Chuang et al., 2011; Schellekens et al., 2012b; Spencer
et al., 2012; Patterson et al., 2013). Preproghrelin mRNA levels
have been shown to be up-regulated in conditions of stress in
both rodents and humans (Asakawa et al., 2001a; Kristenssson
et al., 2006; Rouach et al., 2007; Ochi et al., 2008). In addition,
circulating levels of plasma ghrelin increase in parallel with corti-
costerone following both acute and chronic stressors and remain
elevated after cessation of the stressor (Asakawa et al., 2001a;
Kristenssson et al., 2006; Ochi et al., 2008; Zheng et al., 2009).
This may suggest that ghrelin functions as a potential defence
mechanism against the consequences of stress and to prevent the
manifestation of anxiety and depressive-like symptoms following
chronic stress (Lutter et al., 2008). In line with this hypothesis
was the observed ghrelin-mediated activation of CRF-producing
neurons and enhanced CRF gene expression in the PVN of the
hypothalamus (Cabral et al., 2012). In addition, recent findings
suggest that CRF type 2 receptors may mediate some metabolic
actions of ghrelin (Gershon and Vale, 2013). In this study, a CRF
type 2 receptor selective antagonist, anti-sauvagine-30, blocked
the ghrelin-mediated increase of glucose uptake as well as the
ghrelin-induced enhanced expression of mitochondrial uncou-
pling proteins 2 and 3 (UCP2 and UCP3) in C2C12 cells, a mouse
myoblast cell line. Moreover, both female and male cortistatin
(CST) knockout mice were associated with enhanced levels of
corticosterone compared to control as well as enhanced ACTH
levels in female CST knockout mice. Furthermore, the observed
stimulatory effects on prolactin secretion in the CST knockout
mice were blocked by a GHS-R1a receptor antagonists and CST
knockouts were also correlated with an enhanced level of circu-
lating acyl-ghrelin and increased expression of stomach ghrelin
O-acyl transferase (GOAT) (Cordoba-Chacon et al., 2011). The
neuropeptide CST is able to bind the GHS-R1a receptor and these
findings may further suggest a potential role for CST and ghrelin
in the dysregulation of the HPA axis.
Interestingly, ghrelin knockout mice have been found to be
more anxious in behavioral tests after acute restraint stress
compared with wild-type mice but exhibited a reduced ACTH
response and a lower corticosterone response, suggesting that
in absence of ghrelin the glucocorticoid negative feedback may
be dysregulated (Spencer et al., 2012). Thus, ghrelin may act
to reduce anxiety following an acute stressor by stimulating the
HPA axis at the level of the anterior pituitary and releasing glu-
cocorticoids (Spencer et al., 2012). Interestingly, glucocorticoids
have also been shown to increase the motivation for certain
foods (Dallman et al., 2006; Zimmermann et al., 2007; Kageyama
et al., 2012) as well as to further activate the ghrelinergic system
(Kageyama et al., 2012), reinforcing the feedback theory between
chronic stress and food intake and the involvement of ghrelin.
Together, we can conclude that under normal physiology ghre-
lin may contribute to the stress-induced rise in glucocorticoids,
activating the negative feedback loop in an attempt to prevent
HPA-axis overstimulation.
In line with these findings, increases in ghrelin levels fol-
lowing subcutaneous injections or calorie restriction produced
anxiolytic- and antidepressant-like responses in the elevated plus
maze and forced swim test (Lutter et al., 2008). In the same
study, chronic social defeat stress (CSDS), a model of prolonged
psychosocial stress, enhanced acylated ghrelin levels in mice.
Moreover, social avoidance was increased in GHS-R1a null mice,
suggesting ghrelin to regulate social isolation in response to CSDS
(Lutter et al., 2008). Another study, showed a decreased immobil-
ity of mice in the forced swim test and increased time spent in the
open arms of the elevated plus maze following caloric restriction
or subcutaneous ghrelin injection, reinforcing the anxiolytic and
antidepressant-like effects of elevated plasma ghrelin (Patterson
et al., 2010). In contrast, enhanced ghrelin levels have also
been implicated in the induction of anxiety-like and depressive-
like behavior (Asakawa et al., 2001a; Carlini et al., 2002, 2004;
Kanehisa et al., 2006). These opposing findings are not easily
reconciled but have been attributed to the type and duration of
stressor used (Stengel et al., 2011) and to differential experimen-
tal conditions (for review see Chuang and Zigman, 2010). In these
studies, different types of stress yielded differential circulating
levels of ghrelin, (Stengel et al., 2011). Circulating ghrelin was ele-
vated following metabolic stressors, including caloric restriction,
acute fasting as well as cold exposure, and psychological stres-
sors, such as unpredictable or CSDS. Ghrelin secretion following
these stressors is suggested to be mediated via a sympathoadrenal
response after sympathetic nervous system activation and cate-
cholamine release (Mundinger et al., 2006; Zhao et al., 2010).
However, physical stressors, such as immunological/endotoxin
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injection, abdominal surgery and exercise reduced plasma ghrelin
levels. Further research is needed to delineate the divergent path-
ways underlying the changes in circulating ghrelin levels following
differential stressors.
Only a few clinical studies are available on ghrelin’s role in
stress, anxiety and depression. Despite the limited number of
human studies reported, these also have found that adminis-
tration of ghrelin induces cortisol and ACTH secretion (Takaya
et al., 2000; Arvat et al., 2001). Moreover, elevated circulat-
ing plasma ghrelin levels are equally observed in humans in
response to stress exposure, which were found to correlate with
cortisol levels following the standardized Trier-Social-Stress test
(Rouach et al., 2007). In this study, stress perception and anxi-
ety were enhanced and plasma serum cortisol levels were acutely
increased. Interestingly, cortisol levels correlated with an increase
in ghrelin but not to BMI or eating scores. Interestingly, while
in non-emotional eaters baseline ghrelin exceeded that of high
emotional eaters, ghrelin levels declined in the low emotional
eaters following food intake, but not in emotional eaters, which
may explain sustained eating in high emotional eaters (Raspopow
et al., 2010). Moreover, ghrelin is able to induce an exaggerated
ACTH response, independent of ghrelin-mediated GH response
in Cushing’s disease, a disorder characterized by major weight
gain and chronic hypercortisolism (Monsonego et al., 2001;
Moon et al., 2011). Interestingly, monoaminergic neurotransmit-
ters are both activated by stressors and modulated by ghrelin
(Brunetti et al., 2002; Date et al., 2006; Nonogaki et al., 2006;
Kawakami et al., 2008). For example, dopaminergic cells in the
VTA are sensitive to ghrelin, as well as noradrenergic cells in
the NTS in the brainstem and serotinergic cells in the mid-
brain raphe nuclei (Carlini et al., 2004; Abizaid et al., 2006; Date
et al., 2006). In addition, these ghrelin-sensitive monoamines
mediate the activity of limbic and hypothalamic structures associ-
ated with stress-associated dysfunction (Anisman and Zacharko,
1990; Bremner et al., 1996). This ghrelin-induced activity may
be mediated via specific GHS-R1a heterodimers present on these
monoaminergic cells.
GHRELIN SIGNALING IN FOOD REWARD BEHAVIOR
Ghrelin can promote the predisposition to overeat when pre-
sented with pleasurable energy dense food sources, highlighting
the key role for ghrelin signaling in themotivation to obtain palat-
able food rewards (for review see Skibicka and Dickson, 2011;
Perello and Zigman, 2012; Schellekens et al., 2012b). Indeed,
both peripheral and central ghrelin were shown to enhance hedo-
nic feeding associated with food palatability (Shimbara et al.,
2004; Disse et al., 2010). The expression of the GHS-R1a recep-
tor on midbrain dopaminergic neurons in the VTA and NAcc is
in line with ghrelin’s role in hedonic eating behavior mediated in
the mesolimbic reward system (Guan et al., 1997; Abizaid, 2009;
Skibicka et al., 2011). Indeed, administration of ghrelin into the
VTA and NAcc of rats directly activated these regions and stim-
ulated chow hyperphagia (Naleid et al., 2005). In addition, direct
injection of ghrelin into the VTA of mice significantly increased
the preference for rewarding foods (Egecioglu et al., 2010).
The ghrelin-mediated enhanced preference for rewarding
foods was absent in GHS-R1a knock-out mice (Disse et al., 2010)
and following GHS-R1a antagonist treatment in rats (Egecioglu
et al., 2010), demonstrating GHS-R1a receptor dependence. In
addition, several studies, using conditioned place preference
(CPP) in rodents, have demonstrated that increases in ghre-
lin, following peripheral or central administration and caloric
restriction, enhance the CPP response for HFD but not chow
(Chuang and Zigman, 2010; Egecioglu et al., 2010; Perello et al.,
2010; Disse et al., 2011). Moreover, this was dependent on
the GHS-R1a receptor and an intact VTA region. Furthermore,
the ability of ghrelin to alter food-associated reward has been
assessed using operant conditioning paradigms (Perello et al.,
2010; Skibicka et al., 2011, 2012; Finger et al., 2012a). In these
studies, intra-VTA microinjection of ghrelin significantly stimu-
lated free feeding of chow and increased operant responding to
palatable rewards in rodents (Skibicka et al., 2011), while this
did not occur when ghrelin was directly microinjected into the
NAcc (Dickson et al., 2011; Skibicka et al., 2011). Interestingly,
these studies also demonstrated that ghrelin enhances incen-
tive motivation for sucrose rewards in satiated rats but when
ghrelin signaling is blocked operant responding for sugar in hun-
gry rats returns to the level of satiated rats (Skibicka et al.,
2012). Moreover, GHS-R1a blockade in the VTA decreased the
motivation to obtain sucrose rewards but did not affect fasting
induced chow hyperphagia (Skibicka et al., 2011). This suggests
the selection of rewarding foods and food-motivated behavior is
attributed more specifically to ghrelin’s action on the VTA and
not the NAcc.
Finally, data is accumulating identifying the ghrelinergic sys-
tem tomediate food reward following exposure to stress (Asakawa
et al., 2001a; Chuang and Zigman, 2010; Chuang et al., 2011;
Schellekens et al., 2012b; Spencer et al., 2012; Patterson et al.,
2013). For example, intake of high-fat diet and the CPP response
are increased after exposure to CSDS and absent in GHS-R1a
knockout mice, demonstrating again dependence on intact ghre-
lin signaling (Chuang et al., 2011).
Ghrelin’s ability to modify the rewarding properties of palat-
able foods is mediated via connections to dopamine (DA) neu-
rons and DA release from mesolimbic dopaminergic neurons in
the VTA, which project to the NAcc (Jerlhag et al., 2007; Dickson
et al., 2011; Skibicka and Dickson, 2011). The direct activation of
dopaminergic neurons in the VTA following peripheral and cen-
tral ghrelin administration is in support of this notion (Abizaid
et al., 2006). Moreover, direct injection of ghrelin in the VTA
increases appetitive motivation in rats as shown by an increase
in breakpoint in a progressive ratio schedule and this was shown
to be dependent on intact dopamine signaling (Weinberg et al.,
2011). The ghrelin-mediated increase in food-reinforced behavior
was absent and breakpoints were stabilized following admin-
istration of the dopaminergic neurotoxin 6-hydroxydopamine
(6-OHDA), which significantly depleted striatal dopamine. These
findings demonstrate that activation of dopamine neurons is cru-
cial for the ghrelin-mediated potentiation of food reward in the
mesolimbic reward pathway.
We suggest the involvement of specific heterodimers of the
GHS-R1a receptor with dopamine D1 and D2 receptors, which
are involved in the rewarding aspects of food. These specific GHS-
R1a dimers may mediate ghrelin’s function in the dopaminergic
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reward-signaling pathway within the VTA. Indeed, evidence for
heterodimerization of the GHS-R1a and D1 and D2 receptor was
recently demonstrated (Jiang et al., 2006; Kern et al., 2012) and is
further discussed in this review in the next paragraphs.
POTENTIAL MECHANISM OF STRESS-INDUCED GHRELIN SIGNALING
IN FOOD REWARD BEHAVIOR
It is clear that stress perception and response are modulated by
food intake and diet (Oliver and Wardle, 1999; Gibson, 2006;
Morrison, 2009; Dallman, 2010). The hormone ghrelin is poised
to be involved in the association between stress, food intake and
diet, considering the strong impact of ghrelin on both physio-
logical processes. Interestingly, typical stress-induced metabolic
changes in caloric intake, caloric efficiency and body-weight
gain are absent in GHS-R1a null mice, suggesting that ghre-
lin is important for the metabolic shift required to deal with
the energetic challenge of chronic stress (Patterson et al., 2010).
Moreover, the stress-induced rise in circulating ghrelin may be
behind the phenomenon of “comfort eating” observed in con-
ditions of stress. This hypothesis is in line with the suggested
function of ghrelin as an energy deficit signal, which may have
evolved to favor consumption of calorie-dense palatable foods
and to protect the storage of fat in times of energy insufficiency
(Wells, 2009). Indeed, a continuous peripheral or central ghre-
lin infusion decreases fat utilization as a fuel substrate without
significantly changing energy expenditure or locomotor activity,
ultimately leading to increased adiposity (Tschop et al., 2000).
This may be beneficial under conditions of stress as fat stores
are maintained while energy from carbohydrates is available as
a rapid fuel source, to maintain the defensive response (Kyrou
and Tsigos, 2007). Thus, given that, both stress and ghrelin favor
the use of carbohydrate substrates, which are rapidly oxidized,
and the enhanced secretion of ghrelin following stress, it is likely
that ghrelin contributes to the stress-induced metabolic switch
that favors carbohydrate utilization and the accumulation of fat
stores. Indeed, elevated ghrelin levels following chronic expo-
sure to social stress increase caloric intake, preserve fat stores
and stimulate body weight gain in mice, while under the same
social stress paradigm these metabolic responses are attenuated
or absent in GHS-R1a knockout mice and following pharmaco-
logical blockade of the GHS-R1a receptor (Patterson et al., 2013).
Thus, enhanced ghrelin levels subsequently increase the hedo-
nic and rewarding value of food, which further stimulates the
intake of palatable and caloric dense “comfort” foods, which elic-
its activation of central reward pathways and increases dopamine
signaling. This may mediate metabolic adaptations in response to
the psychosocial stressors to meet the higher energetic demands
and may act to reduce the detrimental effects of these stressors to
promote survival andmay ultimately protect against anxiety- and
depression-like behaviors (Schellekens et al., 2012b).
However, chronic stress can lead to metabolic dysfunction
and aberrant ghrelin signaling, which may ultimately lead to
obesity and a downregulated reward signaling, which may be
causal to the increased sensitivity for the development of psy-
chiatric disorders including depression and anxiety. Thus, ghre-
lin and its receptor, the GHS-R1a receptor, likely represent key
metabolic regulators required to cope with stress and to prevent
excessive anxiety under conditions of chronic stress (Patterson
et al., 2010). However, prolonged exposure to stress and stress-
induced elevations in ghrelinergic signaling may unmask nega-
tive metabolic consequences, leading to long-lasting metabolic
dysfunction and ultimately obesity as well as an associated
sensitivity to the stress-induced psychiatric disorders of anxi-
ety and depression (Patterson et al., 2010; Schellekens et al.,
2012b).
In conclusion, it is clear that classical feeding peptides, includ-
ing ghrelin, are strongly linked in the regulation of appetite and
food intake, the rewarding and motivational drive to eat and the
ability to cope with stress. The precise molecular mechanism link-
ing ghrelin in appetite, reward and stress are not fully elucidated
but it is clear that connections to DA neurons in the mesolimbic
circuitry system are important. We hypothesize that direct inter-
actions of the GHS-R1a receptor with other GPCRs, which have
recently been described, are poised to play a key role in the associ-
ation of these ghrelin-mediated physiological responses in reward
signaling and stress. This review will further discuss the potential
dynamic role for GHS-R1a receptor dimerization in the regula-
tion of ghrelin-specific functions within stress response and food
intake.
MODULATION OF G-PROTEIN COUPLED RECEPTORS VIA
OLIGOMERIZATION
The GHS-R1a receptor belongs to the class A GPCRs, which are
seven transmembrane domain proteins in the plasma membrane
of cells. Conformational changes of the receptor are mediated
via interactions of the GPCR with extracellular small-molecule
ligands, which subsequently results in interaction and activation
of hetero-trimeric intracellular G proteins, which further trans-
duce the downstream signaling events necessary for the cell to
respond to changes in the environment (Pierce et al., 2002).
GPCRs represent the largest family of proteins (>800 members)
in the human genome and are involved in nearly all physiolog-
ical processes, mediating signal transductions across the cellular
membrane. Many GPCRs have been implicated in the pathogen-
esis of human disease and thus, represent attractive targets for the
development of drugs in the pharmaceutical industry. However,
GPCR-targeting drugs are often associated with side effects due
to non-specific activation of other GPCR and non-GPCR tar-
gets and novel pharmacotherapies with enhanced specificity are
urgently sought after.
The concept of the monomeric existence and functioning of
GPCRs, including the GHS-R1a receptor, is firmly established
in literature and has been confirmed by several lines of evidence
from recent studies (Whorton et al., 2007, 2008; Rasmussen et al.,
2011; Damian et al., 2012). However, a large accumulating body
of biochemical and biophysical work now supports the notion
that GPCRs, including class A GPCRs, to which the GHS-R1a
receptor also belongs, do not exclusively exist as monomeric
entities, but extensively crosstalk with each other and form
physiologically relevant oligomers (for review see George et al.,
2002; Franco et al., 2008; Birdsall, 2010; Rozenfeld and Devi,
2010; Gonzalez-Maeso, 2011; Kamal and Jockers, 2011; Rozenfeld
and Devi, 2011; Goddard and Watts, 2012; Herrick-Davis, 2013;
Milligan, 2013; Ward et al., 2013). Indeed, many GPCRs have
been recently found to function as oligomeric complexes,
whereby receptors of the same or different families combine
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to generate homo- or heterodimers or even higher-structure
multimeric complexes (Gupta et al., 2010; Rivero-Muller et al.,
2010; Teitler and Klein, 2012; Jastrzebska et al., 2013). Moreover,
elaborate methods such as fluorescence imaging studies, includ-
ing fluorescence recovery after photobleaching (FRAP) and
total internal reflection fluorescence imaging (TIRF) of single
molecules, as well as intracellular trafficking experiments, have
been explored to confirm both monomeric GPCRs as well as
stable and transient GPCR oligomers (Dorsch et al., 2009; Hern
et al., 2010; Calebiro et al., 2013; Gavalas et al., 2013). Thus,
GPCR oligomerization can now be considered as a fundamental
process in receptor signaling. These GPCR oligomers exhibit
unique pharmacological, biochemical and functional character-
istics including specific signaling cascades, binding cooperativity,
altered receptor internalization as well as changes in recycling
properties (Figure 1) (Hebert and Bouvier, 1998; Terrillon and
Bouvier, 2004; Springael et al., 2005; Urizar et al., 2005; Kent
et al., 2007; Smith and Milligan, 2010; Urizar et al., 2011; de
Poorter et al., 2013). Dimerization of GPCRs may explain the
high constitutive activity of some GPCRs and heterodimerization
may be obligatory for GPCR maturation and trafficking from
the endoplasmic reticulum (ER) to the cell surface to ensure full
receptor functionality [Figure 1(1)], as has been seen for the
GABAB receptors, which is a class C GPCR (Kaupmann et al.,
1998; Cryan and Kaupmann, 2005). The metabotropic GABAB
receptor requires both GABABR1 and GABABR2 receptors for
functional receptor expression on the cell membrane (White et al.,
1998; Galvez et al., 2000, 2001; Duthey et al., 2002). Heterologous
expression of the GABABR1 subunit without the GABABR2
leads to retention of the subunit in the ER, while the GABABR2
subunit alone is expressed on the membrane but not functional.
Heterodimerization of both GABA subunits causes masking of
a retention signal and functional receptor expression (Margeta-
Mitrovic et al., 2000). Similarly, homodimerization of two
β2-adrenergic receptor (β2-AR) subunits is critical for cell surface
expression (Salahpour et al., 2004) and the α1δ-AR is only fully
functional and rescued from the ER when heterodimerized with
a α1β-ARs or β2-AR subunit (Uberti et al., 2005; Hague et al.,
2006). Secondly, receptor dimerization may be dynamically regu-
lated following ligand-mediated receptor activation [Figure 1(2)]
and specific ligand binding may promote or inhibit dimerization
(Horvat et al., 2001; Patel et al., 2002). Alternatively, dimerization
may alter the ligand-binding properties of the receptor complex.
In addition, heterodimerization can have consequences on
allosteric potentiating or attenuating of downstream signal-
ing [Figure 1(3)] as well as influencing positive or negative
co-operativity of ligand binding (Terrillon and Bouvier, 2004).
Moreover, heterodimerization may have the potential to change
G-protein selectivity, alter G-protein coupling [Figure 1(4)] and
alter subsequent downstream signaling and GPCR specificity
(Rozenfeld and Devi, 2011). Interestingly, oligomerized receptor
complexes have been shown to couple to multiple G-proteins,
depending on their cellular environment, thereby conferring
the ability to mediate different intracellular responses to the
same ligand (Rashid et al., 2004). Heterodimerization may also
promote co-internalization of two receptors after the stimulation
of only one protomer. Alternatively, differential desensitization
and β-arrestin recruitment may occur and the presence of a
protomer that is resistant to agonist-promoted endocytosis,
within a heterodimer, can inhibit the internalization of the
complex [Figure 1(5)]. Heterodimer GPCR expression will
likely not be the same in all tissue as not all GPCRs are equally
expressed across various cell types. Therefore, tissue specific
expression of GPCRs will directly regulate dimerization and may
explain the tissue specificity of current GPCR-targeting drugs.
In addition, heterodimerization of GPCRs will likely be different
under pathological human conditions, including obesity and
depression, which may be exploited in the development of novel
ligands with increased specificity and selectivity.
However, current evidence for GPCR interactions are lim-
ited by the fact that the vast majority of studies to date have
been performed in model systems only, which may explain why
GPCR oligomerization is still met with a certain degree of con-
troversy. In addition, during the interpretation of results it has
proved to be very difficult to exclude cross-talk. Therefore, con-
clusions on GPCR oligomerization should be taken with caution.
Although in-depth discussion of the limitations of previous stud-
ies is beyond the scope of this manuscript, several other reviews
discussing this topic exists (Ferre et al., 2009; Birdsall, 2010; Teitler
and Klein, 2012; Milligan, 2013).
While the concept of GPCR is certainly interesting, further
validation at the physiological level is required to convincingly
show that GPCRs indeed form physiologically relevant dimers.
However, demonstrating dimerization in native tissue will be
challenging as GPCRs are not always very highly expressed
endogenously and many GPCRs, including the GHS-R1a recep-
tor, are often associated with high constitutive activity (Holst
et al., 2003; Petersen et al., 2009; Els et al., 2010). Previously, the
acceptance of the functioning of GPCR dimers in vivo was depen-
dent on co-expression of both protomers for functionality or the
abolishment of heteromeric receptor function following genetic
deletion of one protomer (Pin et al., 2007; Ferre et al., 2009; Teitler
and Klein, 2012). Moreover, the complex and dynamic nature of
GPCR dimerization needs to be considered, as dimerization has
been suggested to be both reversible as well as ligand and cell type
dependent (Smith andMilligan, 2010). Thus, additional evidence
demonstrating dimers in vivo is warranted as well as more defined
criteria. The advancement of the field will be complicated by the
fact that many class A GPCRs, including the GHS-R1a recep-
tor are most likely functional as both monomeric units as well
as in heterodimers or oligomeric complexes. The next steps for-
ward for the field will include the development and utilization
of advanced techniques with the capability to extrapolate dimer-
ization from overexpressing model systems to wild-type GPCRs
expressed in native tissues using for example fluorescent ligands
in FRET-based binding assays (Albizu et al., 2010; Cottet et al.,
2012, 2013).
Nevertheless, the implications of enhanced diversity of GPCRs
pharmacology following GPCR oligomerization fundamentally
changes our current knowledge on the structure, activation and
desensitization processes of GPCRs. Ultimately, GPCR dimeriza-
tion is poised to have a dramatic impact on drug development
and screening as it opens up new avenues for the development
of potential novel therapeutics targeting GPCRs, including the
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GHS-R1a receptor (George et al., 2002; Waldhoer et al., 2005;
Panetta and Greenwood, 2008; Casado et al., 2009; Valant et al.,
2009; Rozenfeld and Devi, 2010, 2011).
GHS-R1a RECEPTOR DIMERIZATION AND IMPLICATIONS IN
STRESS AND REWARD SIGNALING
Evidence is accumulating demonstrating dimerization of the
GHS-R1a receptor (Chan and Cheng, 2004; Holst et al., 2005;
Jiang et al., 2006; Takahashi et al., 2006; Chu et al., 2007; Leung
et al., 2007; Chow et al., 2008, 2012; Rediger et al., 2009, 2011;
Kern et al., 2012; Park et al., 2012; Schellekens et al., 2013b).
Dimerization of the GHS-R1a receptor into homo- and/or het-
erodimers has the potential to significantly alter downstream
signaling. Indeed, evidence from mostly heterologous expression
systems and also some native cells has demonstrated that the
GHS-R1a receptor can both traffic and signal as higher-order
oligomeric-complexes dimerized with additional GPCRs involved
in appetite regulation, food reward and stress (Jiang et al., 2006;
Rediger et al., 2009, 2011; Kern et al., 2012; Schellekens et al.,
2013b). This promiscuous dimerization of the GHS-R1a receptor
may function to fine-tune receptor mediated activity via differen-
tial downstream signaling and altered GHS-R1a receptor traffick-
ing. This paragraph describes GHS-R1a receptor dimers known
to date and discusses their potential functional significance. GHS-
R1a dimerization is poised to impact on the regulation of food
intake, hedonic appetite signaling and stress-induced food intake,
in which the ghrelinergic system has been shown to play a major
role.
HOMODIMERS AND HETERODIMERS OF THE GHS-R1a RECEPTOR
Recent research has identified that the GHS-R1a receptor also
has the ability to form homodimers as well as to dimerize with
other GPCRs, forming heterodimers (Table 1). In 2005, Holst and
et al. were the first to propose a model in which the GHS-R1a
receptor functions as a homodimer (Holst et al., 2005). In this
study it was shown that coadministration of a non-endogenous
agonist can act as a neutral (MK-677), positive (L-692,429),
or negative (GHRP-6) modulator of the GHS-R1a receptor in
the presence of the endogenous GHS-R1a agonist ghrelin. The
hypothesized homodimeric model of the GHS-R1a receptor was
supported by the potentiated response of ghrelin upon bind-
ing of growth hormone-releasing hormone (GHRH) to the
GHS-R1a receptor (Casanueva et al., 2008). Co-administration
of GHRH dose-dependently potentiated ghrelin-induced cellu-
lar calcium mobilization and inositol phosphate turnover via
Gq-associated signal transduction without competing with ghre-
lin for binding but enhancing ghrelin’s binding capacity. This
positive binding co-operativity was suggested to occur follow-
ing the interaction of GHRH on an allosteric binding site of
the GHS-R1a receptor, acting as a co-agonist in presence of
the endogenous ligand ghrelin. This allows for an increased
affinity of ghrelin for the GHS-R1a receptor and the simul-
taneous binding of two ghrelin molecules, one to each GHS-
R1a monomer subunit within the homodimer, while in the
absence of ghrelin GHRH binds to the orthosteric binding site
of GHS-R1a (Casanueva et al., 2008). However, it cannot be
ruled out that a direct interaction between the GHS-R1a and
GHRH receptor is responsible for the synergistic interaction,
which is reinforced by the observed potentiation of GHRH-
mediated cAMP production when the GHS-R1a receptor is co-
expressed (Cunha and Mayo, 2002). The homodimeric GHS-R1a
model was confirmed in human embryonic kidney cells (Hek),
using bioluminescence resonance energy transfer (BRET) and
co-immunoprecipitation (Leung et al., 2007). Further evidence
for a direct physical interaction of two GHS-R1a subunits in a
homodimeric complex or a heterodimer between the GHS-R1a
and the GHRH receptor and the existence of such dimers in vivo
is warranted.
In addition, evidence is accumulating suggesting that the
GHS-R1a receptor has the ability to form a heterodimer with
its non-signaling truncated splice variant, the GHS-R1b receptor.
The GHS-R1b receptor is a splice variant with only 5 trans-
membrane domains, lacking the last 2 transmembrane domains
typical for GPCRs, and is primarily localized in the ER (Chan and
Cheng, 2004; Schellekens et al., 2010; Chow et al., 2012). This
dimerization has been shown to attenuate the GHS-R1a/GHS-
R1b receptor pair in the in the ER, which consequently reduces
ghrelin responsiveness and suggests the GHS-R1b receptor to
act as a dominant-negative mutant of the full-length GHS-
R1a receptor (Chan and Cheng, 2004; Chu et al., 2007; Leung
et al., 2007; Chow et al., 2012). The existence of the GHS-
R1a/GHS-R1b heterodimer was reinforced using BRET and in
co-immunoprecipitation experiments and a decreased cell sur-
face expression and decreased constitutive GHS-R1a receptor
activity were observed with increasing expression of GHS-R1b
(Leung et al., 2007; Chow et al., 2012). Interestingly, dimer-
ization of the mu-opioid with truncated splice variants was
recently shown to increase total membrane receptor expres-
sion (Pasternak, 2013; Xu et al., 2013). In addition, a recent
study using purified GHS-R monomers and dimers reconsti-
tuted into lipid discs revealed that the dominant negative effect
of the truncated GHS-R1b receptor is exerted via a confor-
mational restriction of the full-length GHS-R1a protein, which
blocks subsequent G protein activation and β-arrestin recruit-
ment. This clearly demonstrates heteromer-directed selectivity
whereby the specific dimerization impacts on the functional
and structural behavior of the ghrelin receptor (Mary et al.,
2013).
Moreover, the GHS-R1a receptor was found to dimerize
with members of the prostanoid receptor family, which are
involved in modulating vascular activity and inflammatory
responses (Chow et al., 2008). Heterodimers of the GHS-
R1a receptor with the vasodilator prostacyclin (IP) receptor,
the vasoconstrictor prostaglandin E2 receptor subtype EP3-I
(EP3-1) and the thromboxane A2 (TPα) receptor were demon-
strated using co-immunoprecipitations and BRET following tran-
sient co-expression in Hek cells. Decreased GHS-R1a receptor
expression, increase intracellular GHS-R1a receptor localiza-
tion and attenuated constitutive GHS-R1a receptor activation,
were observed upon co-expression of prostanoid receptors,
suggesting a dynamic regulation of GHS-R1a receptor activ-
ity under conditions of increased prostanoid receptors expres-
sion, including vascular inflammation and in atherosclerotic
plaques.
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Table 1 | Homo- and heterodimerization of the GHS-R1a receptor.
Dimer Physical interaction in vitro Cell lines Physical interaction
in/ex vivo
Functional interaction
in vivo
References
GHS-R1a/GHS-R1a Binding and signal
transduction assays
demonstrate allosteric
modulation of ghrelin
signaling: calcium
mobilization, inositol
phosphate turnover, CRE and
SRE transcription assay,
β-arrestin mobilization, BRET,
co-IP
Hek, COS-7 nd nd Holst et al., 2005;
Leung et al., 2007
GHS-R1a/GHS-R1b Subcellular co-localization
using immunocytochemistry;
BRET; ghrelin binding assay;
cell surface expression
ELISA; receptor downstream
signaling; co-IP
Hek, CHO nd nd Chan and Cheng,
2004; Chu et al.,
2007; Leung
et al., 2007;
Chow et al., 2012;
Mary et al., 2013
GHS-R1a/EP3-1 Co-IP; BRET Hek nd nd Chow et al., 2008
GHS-R1a/IP Co-IP; BRET Hek nd nd Chow et al., 2008
GHS-R1a/TPα Co-IP; BRET Hek nd nd Chow et al., 2008
GHS-R1a/SST5 Glucose-stimulated insulin
secretion assay; tr-FRET;
BRET; downstream Gq
(calcium assay) and Gs
(cAMP) signaling
Hek, INS-1SJ nd nd Park et al., 2012
GHS-R1b/NTS1 Co-IP; Co-localization and
receptor trafficking
Cos-7, LC319 nd nd Takahashi et al.,
2006
GHS-R1a/MC3 FRET; ELISA; Co-localization;
binding assay; receptor
trafficking and downstream
Gq (NFAT-luciferase reporter
or calcium assay) and Gs
(cAMP) signaling
Hek, COS-7 Co-expression of MC3
with
lacZ-immunoreactive
cells, representing
GHS-R1a in Arc of
GHS-R1a knock-out
mice
nd Rediger et al.,
2009, 2011;
Schellekens
et al., 2013b
GHS-R1a/D1 Co-IP; Co-localization; BRET;
receptor trafficking and
downstream Gq (calcium
assay) and Gs (cAMP)
signaling
Hek, SK-N-SH Co-expression of D1
with GHS-R1a in the
VTA of
GHSR-IRES-tauGFP
knock-in homozygous
mice
nd Jiang et al., 2006;
Schellekens
et al., 2013b
GHS-R1a/D2 Co-localization; downstream
signaling Gq and Gβγ subunit
of Gi (calcium mobilization
assay and imaging); tr-FRET
Hek, SH-SY5Y,
Primary
hypothalamic
neurons
Co-expression of
D2/GHS-R1a in
hippocampus, striatum
and hypothalamus of
GHSR-IRES-tauGFP
knock-in homozygous
mice; Tr-FRET of
striatum and
hypothalamic tissue in
wt and GHSR−/− mice
Allosteric function for
GHS-R1a on D2-mediated
inhibition of food intake. D2
agonist cabergoline reduces
food intake in mice, which is
absent when GHS-R1a is
pharmacologically blocked or
knocked out in GHS-R1a−/−
mice
Kern et al., 2012
GHS-R1a/5-HT2C Co-localization; receptor
trafficking and downstream
Gq (calcium assay) signaling
Hek nd nd Schellekens
et al., 2013b
Abbreviations: BRET, bioluminescence resonance energy transfer; co-IP, co-immunoprecipitation; CRE, cAMP-responsive element; ELISA, Enzyme-linked immunosor-
bent assay; D1/2, dopamine receptor 1/2; GHS-R, growth hormone secretagogue receptor; IP, prostaglandin (prostacyclin) receptor; EP, prostanoid receptor; MC3,
melanocortin receptor 3; nd, not done; NFAT, nuclear factor of activated T cells; NTS1, neurotensin 1 receptor; SRE, serum-responsive element; TPα, thromboxane
A2; tr-FRET, time-resolved fluorescence resonance energy transfer.
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Furthermore, the GHS-R1b receptor was shown to physi-
cally interact with the neurotensin receptor 1 (NTS1) and this
GHS-R1b/NTS1 heterodimer was suggested to play a role in
the autocrine growth-promoting pathway of non–small cell lung
cancers (Takahashi et al., 2006).
Finally, a recent study indicates that the GHS-R1a recep-
tor also interacts with the somatostatin receptor family, specif-
ically with the somatostatin receptor-5 (SST5) (Park et al.,
2012). Constitutive formation of a GHS-R1a/SST5 heterodimer
was shown using time-resolved FRET and BRET assays, in
which endogenous ghrelin rather than SST, suppressed glucose-
stimulated insulin secretion (GSIS) from pancreatic β-cells. This
was shown to involve a noncanonical ghrelin receptor (GHS-
R1a)–G-protein coupling to Gαi/o and subsequent increased
cAMP production, instead of coupling to the Gαq11 sub-
unit. Moreover, the formation of GHS-R1a/SST5 heterodimer
demonstrated to be dependent on a high ratio of ghrelin
to SST, suggesting a dependence on energy balance, with
enhanced dimer formation following fasting-induced peak ghre-
lin levels. This model predicts that under conditions of low
energy balance the formation of a physiologically relevant
GHS-R1a/SST5 heterodimer establishes an inhibitory tone on
β-cells via ghrelin signaling. This may potentially explain
the differential regulation of islet function by ghrelin and
SST and reinforces the potential dynamic nature of GPCR
dimerization.
A GHS-R1a/MC3 RECEPTOR HETERODIMER IN APPETITE SIGNALING
Evidence for other GHS-R1a heterodimerization pairs is accumu-
lating and to date heterodimerization of the GHS-R1a receptor
with several other hypothalamic GPCRs involved in appetite
signaling has been demonstrated (Rediger et al., 2009, 2011;
Schellekens et al., 2013b). Evidence for a physical interaction
between the MC3 and GHS-R1a receptor was demonstrated,
using enzyme-linked immuno sorbent assay (ELISA) and fluores-
cence resonance energy transfer (FRET) approaches in Hek cells
(Rediger et al., 2009). A more recent study, confirmed dimeriza-
tion of the GHS-R1a receptor in the ARC of the hypothalamus
with the MC3 receptor (Rediger et al., 2011), which is an impor-
tant downstream signaling receptor in the homeostatic control of
food intake and energy balance (Cone et al., 1996; Kishi et al.,
2003; Adan et al., 2006; Yang, 2011). The study demonstrated
a mutual signaling interference upon receptor dimerization.
Ghrelin-induced Gq-mediated GHS-R1a receptor signaling was
significantly reduced upon co-expression of the MC3 receptor in
COS-7 cells, while MC3-mediated cAMP signaling upon admin-
istration of alpha-MSH was enhanced in Hek cells co-expressing
both receptors (Rediger et al., 2011). In addition, a strong atten-
uation of GHS-R1a mediated downstream signaling was shown
upon co-expression of both the MC3 and the GHS-R1a receptors
in Hek cells, which has been suggested to be most likely due to an
attenuation of the dimer pair in the cytosol of Hek cells (Rediger
et al., 2009; Schellekens et al., 2013b). However, no decrease of
membrane receptor expression was observed when both GHS-
R1a and MC3 were expressed in COS-7 cells, as investigated
by ELISA and binding studies, which may indicate cell-specific
effects (Rediger et al., 2011).
DIMERIZATION OF THE GHS-R1a RECEPTORWITH DOPAMINE D1 AND
D2 RECEPTORS
Considering the involvement of ghrelin signaling in other
physiological pathways besides appetite, evidence of heterodimers
of the GHS-R1a with extra-hypothalamic GPCRs involved in
hedonic and rewarding aspects of food intake may be able
to explain crosstalk between the ghrelinergic and mesolimbic
dopaminergic systems. In line with this concept, is the recent
discovery that the GHS-R1a receptor can form dimers with
dopamine D1 and D2 receptors (Jiang et al., 2006; Kern et al.,
2012). The formation of GHS-R1a/D1 or GHS-R1a/D2 receptor
heterodimers are poised to have important functional conse-
quences for the role of ghrelin in the regulation of rewarding
andmotivational eating behavior. The GHS-R1a receptor was first
reported to be able to dimerize with the dopamine D1 recep-
tor (Jiang et al., 2006). In this study, Hek cells expressing both
the GHS-R1a and the D1 receptor displayed a ghrelin-mediated
potentiation of dopamine induced c-AMP accumulation in a
GHS-R dependent manner. Additional evidence for a dimeriza-
tion of the GHS-R1a receptor with the D1 receptor was recently
demonstrated by the attenuation of GHS-R1a-mediated calcium
signaling in Hek cells coexpressing both receptors (Schellekens
et al., 2013b). Together, this may suggest a dimer-induced switch
in GHS-R1a receptor G-protein coupling from Gq to Gs medi-
ated signaling, which has been previously suggested for neuronal
GHS-R1a receptors expressed in NPY cells of the ARC (Kohno
et al., 2003). In addition, co-internalization of the GHS-R1a/D1
receptor pair was also demonstrated following agonist treatment,
further supporting the existence of a GHS-R1/D1 heterodimer
(Schellekens et al., 2013b).
Recently, the D2 receptor has also been found to dimerize
with the GHS-R1a receptor in hypothalamic neurons and to alter
canonical D2 signal transduction resulting in dopamine-induced
calcium mobilization (Kern et al., 2012). Coexpression of the D2
and the GHS-R1a receptor in mouse neuronal hypothalamic neu-
rons was shown as well as in hippocampal and striatal neurons.
In addition, a D2-dependent increase in calcium was observed
in SH-SY5Y neuroblastoma cells and Hek cells overexpressing
both receptors as well as in primary hypothalamic cells using
calcium mobilization assay or calcium imaging to monitor cal-
cium influxes in live cells. A significant increase in intracellular
calcium was observed following treatment with dopamine or a
selective D2 agonist, quinpirole, only in cells co-expressing the
Gi/o-coupled D2 receptor and the Gq-coupled GHS-R1a recep-
tor. Moreover, the dopamine-induced calcium mobilization was
demonstrated to be independent of GHS-R1a-Gq mediated sig-
naling or basal GHS-R1a receptor activity, as Gq siRNA was
unable to inhibit dopamine-induced calcium release in Hek cells,
but the involvement of Gβγ subunits in the calcium mobiliza-
tion from intracellular stores and Gβγ-mediated activation of
PLC was shown. Finally, the functional interaction between the
D2 and GHS-R1a receptor was demonstrated in vitro in Hek
cells as well as in vivo in native hypothalamic mouse tissue using
time resolved fluorescence energy transfer (tr-FRET) and confo-
cal FRET. This study by Kern and colleagues is one of the very few
studies to extrapolate the evidence from overexpressing model
system to naïve tissue with endogenously expressed GHS-R1a
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receptor. Most importantly, the GHS-R1a/D2 heterodimer was
shown to allosterically modify D2-mediated calcium mobiliza-
tion, as the modification of D2-mediated signaling was observed
in the absence of the endogenous GHS-R1a ligand ghrelin, but
was blocked by both D2 and GHS-R1a antagonism. This high-
lights a potential function of the GHS-R1a receptor expressed
in areas of the brain without ghrelin immunoreactivity and
which are considered inaccessible to peripherally produced ghre-
lin. Finally, the functional relevance of the GHS-R1a/D2 dimer
was investigated and it was demonstrated that D2/GHS-R1a pair-
ing attenuates food intake (Kern et al., 2012). Evidence for the
allosteric function for GHS-R1a on D2-mediated inhibition of
food intake was shown using the D2 agonist cabergoline, which
reduced food intake in mice. The cabergoline-induced anorexia
did not require ghrelin but was dependent on GHS-R1a signal-
ing and the GHS-R1a-D2 interaction as it was blocked when the
GHS-R1a receptor was pharmacologically inhibited or knocked
out in GHS-R1a−/− mice. Ghrelin has previously been suggested
to interact with dopamine and to modulate appetitive behavior
within the dopaminergic reward circuitry (Abizaid et al., 2006;
Abizaid, 2009; Weinberg et al., 2011). Indeed, the ghrelinergic sys-
tem has been shown to alter the rewarding value of foods and
to elicit a preference for palatable foods rich in sugar or fats via
modulation of dopamine release (Egecioglu et al., 2010). This
may suggest a role for GHS-R1a receptor dimerization in the
regulation of rewarding qualities of food, independent of home-
ostatic regulation of food intake, and the function of GHS-R1a
heterodimers in the hedonic appetite signaling warrants further
investigation.
EVIDENCE FOR A HETERODIMER BETWEEN THE GHS-R1a RECEPTOR
AND THE 5-HT2C RECEPTOR
Finally, in a recent study evidence was presented for a novel
heterodimer between the GHS-R1a receptor and the 5-HT2C
receptor (Schellekens et al., 2013b). Here it was shown that GHS-
R1a-mediated calciummobilization following ghrelin orMK0677
treatment, was attenuated following interaction with the fully
active unedited form of the 5-HT2C receptor but not follow-
ing co-expression of a partially edited isoform of the 5-HT2C
receptor. Editing of the 5-HT2C receptor has been demonstrated
to lead to a decreased receptor functioning (Burns et al., 1997;
Niswender et al., 1999; Berg et al., 2008; Olaghere da Silva
et al., 2010; Schellekens et al., 2012a). This may suggest the
possibility that alteration of the 5-HT2C receptor editing profile
can equally impact on GHS-R1a receptor signaling in vivo. The
attenuated GHS-R1a receptor signaling was completely restored
following pharmacological blockade of the 5-HT2C receptor.
Moreover, ligand-mediated co-internalization of the GHS-R1a/5-
HT2C receptor pair was demonstrated in Hek cells generated to
express the receptor pair. Further evidence for a GHS-R1a/5-
HT2C receptor dimer was shown when a potent specific inverse
agonist of the GHS-R1a receptor, [D-Arg1, D-Phe5,D-Trp7,9,
Leu11]-substance P, was able to increase signaling in heterologous
cells co-expressing the GHS-R1a/5-HT2C receptor dimer follow-
ing serotonin (5-HT, 5-hydroxytryptamine) treatment, while no
potentiation of Gq-mediated calcium mobilization was observed
in cells solely expressing the 5-HT2C receptor. The inverse
GHS-R1a agonist suppresses ligand-independent basal activity
of the GHS-R1a receptor (Holst et al., 2003) and is known to
increase GHS-R1a receptor membrane expression (Liu et al.,
2007). This data demonstrates a co-recruitment of the 5-HT2C
receptor with the GHS-R1a receptor to the cellular membrane,
upon treatment with the inverse GHS-R1a receptor agonist, indi-
cating a direct physical interaction. Together, this suggests a
potential novel mechanism of 5-HT2C mediated attenuation of
the GHS-R1a receptor. Both the GHS-R1a receptor and the 5-
HT2C receptor are involved in feeding behavior. Activation of
the 5-HT2C receptor signaling mediates hypophagia (Lam et al.,
2008). Interestingly the 5-HT2C receptor also mediates anxiety
like behavior (Heisler et al., 2007b). It is therefore tempting
to speculate that GHS-R1a/5-HT2C receptor heterodimerization
may play a role in homeostatic appetite signaling and in stress-
induced food intake. A recent study demonstrated an attenuation
of ghrelin’s orexigenic effect following direct PVN administra-
tion of 5-HT in rats, which supports a potential significant role
for the GHS-R1a/5-HT2C receptor dimer pair in appetite regula-
tion in vivo (Currie et al., 2010). Further investigations into the
extent and functional relevance of GHS-R1a/5-HT2C dimeriza-
tion in vivo are now warranted.
CONCLUSION
Obesity is a growing concern increasing in prevalence world-
wide. In addition, humans are increasingly faced with excessive
psychological stress in modern day society, which appears to
have synergistic effects with the obesity epidemic. The orexigenic
gastric-derived hormone ghrelin plays a key role in the home-
ostatic control of appetite, rewarding and motivational aspects
of food intake as well as stress-induced food reward behaviors,
linking eating behavior with both stress and hedonic signaling
(for review see Chuang and Zigman, 2010; Diz-Chaves, 2011;
Perello and Zigman, 2012; Schellekens et al., 2012b). Ghrelin sig-
nals via the peripheral and central expressed GHS-R1a receptor,
which has recently shown to form heterodimers with several addi-
tional GPCRs involved in appetite signaling and reward, including
the truncated GHS-R1b receptor, the MC3 receptor, D1 and D2
receptors, and more recently, the 5-HT2C receptor (Jiang et al.,
2006; Rediger et al., 2009, 2011; Kern et al., 2012; Schellekens
et al., 2013b). Heterodimerization of the GHS-R1a receptor may
function to fine-tune GHS-R1a mediated signaling and could
potentially explain crosstalk between ghrelin and monoamin-
ergic neurotransmission in the brain. Heterodimerization may
regulate GHS-R1a receptor function via stabilization of specific
receptor conformations, altering preferential G-protein coupling
and lead to heteromer-specific signal transduction and receptor
trafficking.
Overall, GHS-R1a heterodimerization may modulate specific
signaling pathways andGHS-R1a receptor functionalities or serve
as an allosteric mechanism able to regulate signaling pathways of
the other receptor, independently of ghrelin binding. The latter
has been demonstrated recently for the GHS-R1a/D2 heterodimer
by the observation that GHS-R1a receptor expression alone was
able to allosterically mediate D2 receptor signaling (Kern et al.,
2012). In addition, this study also demonstrated that dopamine-
mediated anorexia was inhibited following the pharmacological
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blockade of the GHS-R1a receptor. Interestingly, D2 receptor
mutations have demonstrated to attenuate dopamine signaling
and to be associated with human obesity (Tataranni et al., 2001).
Moreover, since central ghrelin signaling has been shown to be
involved in the control of reward seeking behaviors for food, alco-
hol, and drugs of abuse by modulating mesolimbic dopaminergic
reward signaling, the existence of GHS-R1a/D2 heterodimers
would offer a potential mechanism to explain the effects of ghre-
lin on reward. Moreover, dopamine signaling has been shown to
be crucial for ghrelin-mediated increase in food reward. Thus, the
GHS-R1a/D2 dimer would represent a new molecular target and
rational for the development of ghrelin-based therapeutic inter-
ventions in conditions associated with abnormal reward-seeking
behavior. Moreover, circulating ghrelin levels are enhanced fol-
lowing acute stress and interactions of the GHS-R1a receptor with
other GPCRs mediating the rewarding and motivational drive
to eat, such as the D1 and D2 receptor, may activate pathways
necessary to cope with stress.
The stress-induced increase in ghrelin has been suggested to
be able to reduce anxiety under conditions of acute stress follow-
ing the stimulation of the HPA and the neurobiology of stress and
appetite regulation overlap significantly. The 5-HT2C receptor is
expressed in the ARC of the hypothalamusmediating hypophagia
(Lam et al., 2008) as well as on CRF neurons in the PVN and simi-
lar to ghrelin, 5-HT2C receptor activation here, mediates secretion
of CRF (Heisler et al., 2007a). Moreover, 5-HT2C receptor knock-
down decreases anxiety-like behavior (Heisler et al., 2007b), while
mice with genetic ablation of ghrelin exhibit a more anxious phe-
notype (Spencer et al., 2012). Together this may suggest a func-
tional role for the recently identified GHS-R1a/5-HT2C dimer in
HPA axis activation, which warrants further investigations.
Targeting GHS-R1a receptor dimers within the metabolic reg-
ulation of food intake and food reward is poised to impact on
the dopamine-related reward systems and stress response and
therefore not only provides exiting opportunities for future phar-
macotherapies in the treatment of metabolic and eating disorders,
but also in psychiatric disorders with dysregulated DA signal-
ing. The recent findings demonstrating heterodimerization of the
GHS-R1a under certain conditions and reinforces the concept
that GPCR signaling is most likely a dynamic process, which is
dependent on physiological context. Understanding the contri-
butions of the interactions between the serotinergic and ghre-
linergic system on the dopaminergic output following stress and
maladaptive food intake and the role of the recently identified
GHS-R1a heterodimer complexes herein, will increase our knowl-
edge of the pathology of obesity and anxiety and its bidirectional
relationship. While the GHS-R1a receptor is expressed ubiqui-
tously in the brain at multiple sites involved in both food intake
behavior and stress, the MC3, 5-HT2C, D1 and D2 receptors have
a more localized expression. For example the MC3 is expressed
in the hypothalamus only, which means that the GHS-R1a/MC3
dimer potentially only has an impact on homeostatic regula-
tion of appetite. The exact central locations of GHS-R1a complex
formation remain to be determined.
Noteworthy, evidence supporting a physiologically relevant
interaction and physiological role for GHS-R1a heterodimers is
limited. It has been notoriously difficult to establish the existence
of the vast majority of GPCR dimers in vivo due to the exper-
imental challenge of differentiating a direct physical interaction
from receptor crosstalk and this remain somewhat controversial.
Nevertheless, the conceptually important premise of promiscuous
GHS-R1a heterodimerization confers unique pharmacological
and functional properties to the receptor, significantly enhancing
the pharmacological diversity and with it the potential for novel
therapies. Additional research is warranted to further investigate
the physiological relevance of GHS-R1a dimers in metabolic eat-
ing disorders, such as obesity, and under conditions of stress.
Further studies are required to determine whether the dimer-
ization in the in vitro biochemical assays translates to the func-
tionally relevant dimers in vivo. Nevertheless, the oligomerization
characteristic of GPCRs, including the GHS-R1a receptor, creates
a broader regulatory complexity and has therapeutically impor-
tant implication as heterodimers provide novel pharmacological
targets and thus may be exploited to create more specific thera-
peutic drugs (Prinster et al., 2005). Thus, althoughmore evidence
and functional relevance for GPCR dimerization in vivo as well as
methods to deal with the most likely dynamic nature of physi-
cal receptor interaction is warranted, the achievements of the last
few years on GPCR dimerization provide the foundation of what
promises to be very exciting times for GPCR-targeted molecular
pharmacology. In addition, the field of heterodimer specific phar-
macology and drug discovery is set to change significantly with
these new findings.
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